Man lives for 100 days with artificial titanium heart in successful new trial
An Australian man lived for 100 days with an artificial titanium heart while he awaited a donor transplant, the longest period to date of someone with the technology.
The patient, a man in his 40s who declined to be identified, received the implant during surgery at St. Vincent's Hospital Sydney last November.
In February, he became the first person worldwide to leave hospital with the device, which kept him alive until a heart donor became available earlier this month.
According to a statement issued Wednesday by St Vincent's Hospital, Monash University and BiVACOR, the US-Australian company behind the device, the man, who had severe heart failure, was 'recovering well.'
The ability of the device to sustain him for so long is being celebrated as a sign the artificial heart could potentially offer a long-term option for people suffering heart failure. The device is still being trialed and has not yet been approved for general use.
BiVACOR's founder, Australian bioengineer Daniel Timms, who invented the device following his father's death from heart disease, said it was 'exhilarating to see decades of work come to fruition.'
'The entire BiVACOR team is deeply grateful to the patient and his family for placing their trust in our Total Artificial Heart,' he said in the statement. 'Their bravery will pave the way for countless more patients to receive this lifesaving technology.'
The BiVACOR Total Artificial Heart (TAH) has a single moving part, a levitated rotor that's held in place by magnets. As the name suggests, it's constructed from titanium and there are no valves or mechanical bearings that may be susceptible to wear.
It pumps blood to the body and the lungs, replacing both ventricles of a failing heart.
Cardiovascular diseases are the leading cause of death globally killing around 18 million people each year, according to the World Health Organization.
The long-term ambition is to use the device to save more people who languish on waiting lists for suitable donors. According to the US Health Department, about 3,500 people received heart transplants in 2024. Around 4,400 joined the waiting list the same year.
Professor Chris Hayward, from the Victor Chang Cardiac Research Institute, said the BiVACOR heart ushered in 'a whole new ball game for heart transplants.'
'Within the next decade we will see the artificial heart becoming the alternative for patients who are unable to wait for a donor heart or when a donor heart is simply not available,' said Hayward, who is overseeing the Australian patient's recovery and was involved in preparing the device for clinical trials.
The device has already been tested in the Food and Drug Administration's Early Feasibility Study in the United States, which saw five patients successfully implanted with the device.
The first was last July, when a 58-year-old man suffering end-stage heart failure received the implant during surgery at Texas Medical Center. It kept him alive for eight days until a donor was available.
Four other patients followed in the study, which examined the safety and performance of the device, while they waited for a donor transplant. It's hoped the trial will expand to 15 patients.
The Australian implant was the first in a series planned by Monash University's Artificial Heart Frontiers Program, a 50 million Australian dollar ($31 million) program to develop and commercialize three devices to treat heart failure.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Controversial 'alcohol alternative' coming to Woolworths this month: 'Impacts can vary'
A plant-based product promising relaxation, mood boosts, and even a safer alternative to alcohol is set to hit Woolworths shelves this month. A bitter-tasting drink made from the root of a Pacific Island plant, kava has long been used in traditional ceremonies across Polynesia. Now, it's being marketed as a wellness beverage in supermarkets across Australia. But not everyone is convinced. While the plant is often marketed as natural and non-intoxicating, the science behind kava's safety and efficacy is still emerging, particularly when it comes to modern, concentrated formulations, Dr Blair Aitken from Swinburne's Centre for Mental Health and Brain Science, told Yahoo News. Some hail its calming effects and link the substance to lower anxiety, while others warn that these commercialised forms come with poorly understood health risks and little regulation. "Kava contains active compounds called kavalactones, which can have a calming effect by influencing brain chemicals like gamma-aminobutyric acid (GABA) and dopamine," Dr Aitken explained. "It may reduce anxiety and promote relaxation without the intoxicating effects of alcohol, but its impact can vary widely depending on the formulation and dosage. "Kavalactones increase levels of GABA, a neurotransmitter that helps calm the brain and nervous system. They also enhance dopamine levels, which may improve overall mood and create a mild sense of well-being, and they slow down brain signals by blocking sodium and calcium channels, reducing overactivity in the nervous system." Woolworths is the latest major retailer to introduce kava-based products, joining Coles, which already offers a small range, including powders and capsules. The move is part of a broader trend following the federal government's 2021 import pilot program, which eased access to kava across most of the country. Commercial availability has since expanded, with products now found in chemists, health food stores, and increasingly on supermarket shelves. Unlike alcohol, Dr Aitken said, kava doesn't typically impair motor skills or reaction time when used in traditional or therapeutic amounts. "Its effects are more subtle and stabilising rather than intoxicating," he said. However there are still concerns, particularly when it comes to modern extracts and non-traditional preparations, he added. "There is no well-established toxic dose for kava," Dr Aitken said. "Most capsule formulations range from 50 to 100 mg of kavalactones, with a recommended maximum daily dose of 250 mg." "When prepared traditionally and used within recommended amounts, kava is considered safe by both the World Health Organisation and the Australian government. The substance shows few serious side effects when used short-term at recommended doses,' he said. "However, higher risks may occur with modern extracts, combined use with alcohol or medications, high doses, or use by individuals with underlying liver issues." Research into kava's use for treating anxiety has yielded mixed results. "While earlier trials showed promising results in generalised anxiety disorder, a more recent study by the same research group did not replicate those findings," Aitken said. "Kava appears more effective for situational or mild anxiety, rather than as a first-line treatment for diagnosed, clinically relevant anxiety." 🍎 Woolworths customers spark debate over brazen fruit act 💰 Woolworths responds to glaring pricing issue 👩 Aussie mum's sad supermarket confession: 'Do anything for my children' In Australia, kava is regulated as a food when imported for personal use or through approved programs. The Northern Territory bans personal importation and restricts use under separate legislation due to concerns about misuse and harm. Other states and territories allow limited personal use under federal guidelines. Internationally, the substance has a range of legal classifications — it's listed as a psychoactive substance in New Zealand, for example. The way kava is prepared also plays a key role in its safety. Traditional water-based methods extract kavalactones while leaving behind many of the potentially harmful compounds. In contrast, modern commercial products sometimes use alcohol or acetone as solvents, which can extract flavokavains—compounds that may negatively affect the liver and nervous system. Some also include stems or leaves, which have different and more toxic chemical profiles than the root. Coles offers several kava products, though not all have clear labelling around kavalactone content. For example, FijiKava Noble Root Powder contains an estimated 70–150 mg per 2.5g serving, but the exact amount is not specified. The TakiMai 50mL kava shot also lacks precise dosing information. By contrast, Bioglan Kava capsules sold at Chemist Warehouse offer standardised dosing, with 60 mg per capsule and a recommended daily intake of 60–120 mg — well within safe limits. "Transparent labelling is essential," Dr Aitken said. "Consumers should monitor their intake carefully and stay within the recommended daily limit." Dr Aitken is also a member of the International Council on Alcohol, Drugs and Traffic Safety (ICADTS) Special Interest Group for 'Driver State Monitoring Systems,' and noted that while kava is not typically associated with impairment, more research is needed around its effects on alertness and driving, especially at higher doses or in combination with other substances. With Woolworths set to join the expanding commercial kava market, health professionals are calling for increased transparency, clearer consumer education and regulatory oversight. "Just because it's natural doesn't mean it's risk-free," he said. Love Australia's weird and wonderful environment? 🐊🦘😳 Get our new newsletter showcasing the week's best stories.
Yahoo
4 hours ago
- Yahoo
The Church of Jesus Christ strengthens global effort, doubling initial projections, helping improve the lives of more than 21 million women and children worldwide
SALT LAKE CITY , June 6, 2025 /PRNewswire/ -- As part of its ongoing responsibility to care for those in need, The Church of Jesus Christ of Latter-day Saints is bolstering its global initiative to improve the well-being of women and children. During meetings on Temple Square in Salt Lake City, Utah, on Thursday, June 5, 2025, Relief Society General President Camille N. Johnson told representatives from eight global humanitarian organizations that the Church is donating another US$63.4 million to this worldwide project first announced in 2023. Last year, the Church announced a $55.8 million donation as part of this effort. "Collaboration remains at the heart of this initiative; we create the greatest impact through our united efforts. Together, we look forward to another year of creating healthier futures for women and children and strengthening communities," President Johnson said. During the gathering, representatives shared key results from 2024, highlighting significant progress: 21.2 million children and mothers received vitamins. 1.87 million children were screened for malnutrition and treated if needed. 1.6 million mothers were trained in nutrition best practices. 219,000 pregnant mothers received prenatal care. 141,000 families received seeds, training or now have home gardens with more nutrient-dense foods. 41,000 people were trained in improved hygiene behaviors. 17,000 government health workers were trained to support maternal and newborn care, child nutrition, breastfeeding, and the administration of vitamins. 6,800 people benefited from improved water and sanitation facilities. 159 newborns were resuscitated at birth. 125 health facilities were trained to track clinical cases of malnutrition and provide treatment. The Church has taken a leadership role in convening eight globally recognized nonprofits, and as part of four groups, each focused on projects benefiting women and children. These organizations are: CARE International, Catholic Relief Services (CRS), Helen Keller Intl, iDE, MAP International, Save the Children, The Hunger Project, and Vitamin Angels. The four groups and their areas of focus and objectives are as follows Group 1: Helen Keller Intl, Vitamin Angels, iDEObjective: Increase access to nutritious foods, vitamins, and medications in 12 countries (Bangladesh, Cambodia, Democratic Republic of the Congo, Ghana, Kenya, Mali, Nepal, Nigeria, Philippines, Senegal, Sierra Leone, and Zambia). Group 2: CRS, The Hunger Project, MAP InternationalObjective: Improve maternal newborn care, water, sanitation, and hygiene, and nutrition in Ghana. Group 3: Save the Children, MAP InternationalObjective: Improve maternal newborn care and nutrition in Sierra Leone and Zambia. Group 4: CARE, iDE, MAP InternationalObjective: Improve agriculture and nutrition and upgrade medical clinics in Nepal. "With our global reach, we are uniquely positioned to foster collaboration among these eight organizations. By leveraging our individual strengths and resources, we amplify our collective impact," said Blaine Maxfield, managing director of Welfare and Self-Reliance Services. "What a blessing it is to come together to serve God's children around the world." The announcement of new funding was part of activities, including an expert panel discussion scheduled for later in the day on Thursday, June 5, led by Bishop L. Todd Budge, Second Counselor in the Church's Presiding Bishopric. The panel focused on health and nutrition for women and children. The panelists were President Camille Johnson, Blaine Maxfield, Sharon Eubank (director of Church Humanitarian Services), Sarah Bouchie (CEO of Helen Keller Intl), Ana Céspedes (CEO of Vitamin Angels), Lizz Welch (CEO of iDE), and Abena Amedormey (Ghana country representative for CRS). In 2023, the First Presidency asked the Relief Society to lead this global effort. President Russell M. Nelson has told women that they have a divine endowment to change lives. He said, "I am inspired by your diligence, dynamic leadership, and your ability to see a need and meet it." Members of The Church of Jesus Christ of Latter-day Saints believe in following the Savior's two great commandments: to love God and to love our neighbor. As part of this mandate, we seek to maximize our impact so our efforts bless not only those who receive help but also their families and communities. For more information on the Church's effort to care for those in need, please visit the most recent "Caring for Those in Need" summary. View original content to download multimedia: SOURCE The Church of Jesus Christ of Latter-day Saints Sign in to access your portfolio
Yahoo
8 hours ago
- Yahoo
As measles spreads across the Americas, outbreaks in Mexico and Canada have also turned deadly
As measles cases in the United States continue to mount, neighboring countries Canada and Mexico are also experiencing significant outbreaks – all of which have been linked to at least one death. On Thursday, the chief medical officer of health of the Canadian province Ontario announced that an infant who was born prematurely with a measles infection had died. 'The infant contracted the virus before birth from their mother, who had not received the measles, mumps and rubella (MMR) vaccine,' Dr. Kieran Moore said in a statement. 'While measles may have been a contributing factor in both the premature birth and death, the infant also faced other serious medical complications unrelated to the virus.' At least four people have died from measles in Mexico in 2025, and three people have died in the US: two children in Texas and one adult in New Mexico, all of whom were unvaccinated. This years' measles outbreaks are the biggest that Canada and Mexico have seen in decades, and the World Health Organization has warned that the 'overall risk of measles in the Americas Region is considered high.' Low vaccination rates are a key driver of this elevated risk assessment, the agency said. Mexico has reported at least 1,520 measles cases as of late May, according to data from the Pan American Health Organization. Canada reached measles elimination status in 1998, meaning that there has not been continuous spread of the virus for more than a year. But there have already been more cases reported so far this year than there were in the previous 27 years combined. At least 2,755 measles cases have been reported in Canada so far this year, according to federal data that was last updated on Monday, the vast majority of those which have been in Ontario residents. And the US has reported at least 1,168 measles cases so far this year, according to federal data published Friday – nearly 80% of which are associated with an outbreak centered in West Texas that has spread to New Mexico, Oklahoma and possibly Canada. It's the second highest number of cases that the US has reported since achieving measles elimination status in 2000. Significant shares of the measles outbreaks in the US, Canada and Mexico have been concentrated in Mennonite communities that are closely connected to each other – and that have historically had low vaccination rates due largely to minimal interactions with formal health care systems. However, in a recent webinar, experts from the Pan American Health Organization did not formally link outbreaks in the three countries to each other. 'The outbreak [in Mexico] started in Chihuahua, at the heart of Mennonite communities, who were very close to Texas through the border, but they're also close to other Mennonite communities in Canada,' Dr. Alvaro Whittembury, regional adviser for the Comprehensive Immunization Special Program, said in a presentation on Wednesday. 'It's important to show that although at first the outbreak starts in Mennonite communities … the vast majority of cases are outside of these communities, and they are sustained in the general population.' Only a small share of confirmed cases in the Americas have identified genetic sequences, experts from the Pan American Health Organization said, and there haven't been enough identical sequences to explicitly link cases across countries. In April, Mexico issued a warning for people traveling to the US and Canada due to high measles case rates. The US Centers for Disease Control and Prevention has also stepped up its guidance for travelers, advising that anyone traveling internationally should be vaccinated with two doses of the MMR vaccine. 'Anyone who is unvaccinated is at risk and I urge everyone, but especially those who may become pregnant, to ensure they have received two doses of the MMR vaccine, which will protect both a parent and baby,' Moore said in his statement Thursday. 'This vaccine has been safely used for over 50 years and is highly effective. Two doses provide nearly 100 per cent protection.'
